Strahlentherapie des Prostatakarzinoms in der Primärsituation

Zusammenfassung

In der Primärtherapie des Prostatakarzinoms stehen verschiedene Stadienadaptierte radioonkologische Therapiekonzepte zur Verfügung, teilweise kombiniert mit einer antiandrogenen Therapie (ADT). Fortschritte in der bildgesteuerten (IGRT) und der intensitätsmodulierten Strahlentherapie (IMRT) und der Brachytherapie ermöglichen die Applikation hoher Strahlendosen und damit eine hohe Tumorkontrolle bei gleichzeitig günstigem Nebenwirkungsprofil.

• Literatur

• 1 Heesterman BL, Aben KKH, de Jong IJ. et al. Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review. BMC Cancer 2023; 23 (1) 398
• 2 Chen RC, Basak R, Meyer AM. et al. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA 2017; 317 (11) 1141-1150
• 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe) A. S3-Leitlinie Prostatakarzinom. Accessed January 06, 2024 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
• 4 Zelefsky MJ, Kollmeier M, Cox B. et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84 (1) 125-129
• 5 Dearnaley D, Syndikus I, Mossop H. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17 (8) 1047-1060
• 6 Kishan AU, Ma TM, Lamb JM. et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol 2023; 9 (3) 365-373
• 7 Ristau J, Hörner-Rieber J, Buchele C. et al. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial. Radiat Oncol 2022; 17 (1) 75
• 8 Tree AC, Ostler P, van der Voet H. et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an openlabel, randomised, phase 3, non-inferiority trial. Lancet Oncol 2022; 23 (10) 1308-1320
• 9 Kerkmeijer LGW, Groen VH, Pos FJ. et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol 2021; 39 (7) 787-796
• 10 Zamboglou C, Spohn SKB, Ruf J. et al. PSMAPET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020–01). Int J Radiat Oncol Biol Phys 2022; 113 (5) 1025-1035
• 11 Brand DH, Tree AC, Ostler P. et al. Intensitymodulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019; 20 (11) 1531-1543
• 12 Schaeffer EM, Srinivas S, Adra N. et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21 (10) 1067-1096
• 13 Roach 3 rd M. et al. Short-term neoadjuvant androgen deprivation therapy and externalbeam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26 (4) 585-591
• 14 Bolla M, Collette L, Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360 (9327) 103-106
• 15 Denham JW, Steigler An. Lamb DS. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6 (11) 841-850
• 16 Bolla M, Maingon P, Carrie C. et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol 2016; 34 (15) 1748-1756
• 17 D’Amico AV, Desjardin A, Chung A. et al. Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy. Semin Urol Oncol 1998; 16 (3) 153-159
• 18 Hamdy FC, Donovan JL. Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply. N Engl J Med 2023; 389 (1) 92
• 19 Morikawa LK, Roach 3 rd M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 2011; 80 (1) 6-16
• 20 Hoskin PJ, Rojas AM, Ostler P. et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol 2021; 154: 214-219